US healthcare group Abbott bets on cancer screening technology in $23bn deal
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest acquisition in almost a decade. Exact’s main product — Cologuard
